West Pharmaceutical Services (NYSE:WST) Issues FY22 Earnings Guidance

West Pharmaceutical Services (NYSE:WSTGet Rating) issued an update on its FY22 earnings guidance on Thursday morning. The company provided EPS guidance of $9.30 to $9.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.26.

Shares of WST stock traded down $10.30 on Friday, hitting $315.06. The company’s stock had a trading volume of 660,813 shares, compared to its average volume of 402,493. The company has a market capitalization of $23.42 billion, a PE ratio of 35.01, a PEG ratio of 3.72 and a beta of 1.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.30 and a current ratio of 2.93. West Pharmaceutical Services has a fifty-two week low of $308.36 and a fifty-two week high of $475.35. The stock’s 50 day moving average is $384.72 and its 200-day moving average is $406.14.

West Pharmaceutical Services (NYSE:WSTGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.18. The firm had revenue of $720.00 million for the quarter, compared to the consensus estimate of $720.92 million. West Pharmaceutical Services had a net margin of 23.37% and a return on equity of 31.20%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.05 earnings per share. On average, research analysts forecast that West Pharmaceutical Services will post 9.28 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 3rd. Shareholders of record on Wednesday, July 20th will be paid a dividend of $0.18 per share. The ex-dividend date is Tuesday, July 19th. This represents a $0.72 dividend on an annualized basis and a yield of 0.23%. West Pharmaceutical Services’s payout ratio is 8.00%.

WST has been the topic of a number of analyst reports. Zacks Investment Research downgraded shares of West Pharmaceutical Services from a buy rating to a hold rating and set a $450.00 price objective on the stock. in a research note on Saturday, January 8th. StockNews.com downgraded shares of West Pharmaceutical Services from a buy rating to a hold rating in a research note on Thursday. Finally, William Blair restated an outperform rating on shares of West Pharmaceutical Services in a research note on Tuesday, February 22nd.

In other news, VP Quintin J. Lai sold 8,016 shares of the firm’s stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $371.69, for a total value of $2,979,467.04. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.66% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Deutsche Bank AG raised its holdings in West Pharmaceutical Services by 4.1% in the 4th quarter. Deutsche Bank AG now owns 313,547 shares of the medical instruments supplier’s stock valued at $147,057,000 after buying an additional 12,432 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in West Pharmaceutical Services by 9.5% during the 4th quarter. Parametric Portfolio Associates LLC now owns 255,219 shares of the medical instruments supplier’s stock worth $119,700,000 after purchasing an additional 22,221 shares during the last quarter. Barclays PLC raised its holdings in West Pharmaceutical Services by 22.3% during the 4th quarter. Barclays PLC now owns 141,174 shares of the medical instruments supplier’s stock worth $66,211,000 after purchasing an additional 25,701 shares during the last quarter. California State Teachers Retirement System raised its holdings in West Pharmaceutical Services by 1.2% during the 4th quarter. California State Teachers Retirement System now owns 129,906 shares of the medical instruments supplier’s stock worth $60,927,000 after purchasing an additional 1,545 shares during the last quarter. Finally, State of Tennessee Treasury Department raised its holdings in West Pharmaceutical Services by 19.8% during the 4th quarter. State of Tennessee Treasury Department now owns 26,492 shares of the medical instruments supplier’s stock worth $12,425,000 after purchasing an additional 4,386 shares during the last quarter. Institutional investors and hedge funds own 91.24% of the company’s stock.

West Pharmaceutical Services Company Profile (Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Articles

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.